Macleods Laboratories Private Limited - Due diligence report

A 360° intelligence report on Macleod Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distres…

1987-12-16 Mumabi, Maharashtra Active Unlisted Active Compliant
Share
ML Macleods Laboratories Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Macleod Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
90/100
Trust Score
Low Risk

Macleod Pharmaceuticals is assessed as Low Risk with a Trust Score of 90/100. Macleod Pharmaceuticals is an active private limited indian non-government company incorporated in 1987, operating in the Real Estate and Construction sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 20 Jul 2026 from the latest processed filings. Macleods Laboratories Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
90/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 1 satisfied (12.50 cr).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of India1 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
BANWARILAL MURLIDHAR BAWRI 01234567 Director 01/04/2018 6 yrs Approved
RAJENDRA MURLIDHAR AGARWAL 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 38+ years.
Active GST registration(s).
Distress signals & risk flags
No critical warning flags detected in the available data.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment88/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 7 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
17 Mar 2006
Charge satisfied
State Bank Of India
18 Dec 2000
Charge created
State Bank Of India - 12.50 cr
16 Dec 1987
Incorporated
Registered with Roc Mumbai
Director appointed
BANWARILAL MURLIDHAR BAWRI (Director)
Director appointed
RAJENDRA MURLIDHAR AGARWAL (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Bansari Real Estate Private Limited U70103GJ2017PTC099997 Ahmedabad, Gujarat, India
Ramakrishna Impex Private Limited U27209MH2000PTC180161 Mumbai, Maharashtra, India
Kusalava Realty Private Limited U70102AP2007PTC056263 Vijayawada, Andhra Pradesh, India
El Shadai Business Enterprises Private Limited U52110KL2007PTC020717 Thrissur, Kerala, India
Mayank Real Estate Developers Private Limited U45201UP2005PTC030917 Uttar Pradesh, Uttar Pradesh, India
Elgee Technologies Private Limited U05190KA2000PTC026588 Bangalore, Karnataka, India
Gomti Securities Private Limited U65921MH1991PTC062655 Mumbai, Maharashtra, India
Classic Lamps Industries Private Limited U31909DL2006PTC145565 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Macleod Pharmaceuticals before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Macleod Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Macleod Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 90/100, distress signals and MSME payment-delay disclosures - know whether Macleod Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Macleod Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Macleod Pharmaceuticals an active company?

Macleod Pharmaceuticals has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Macleod Pharmaceuticals financially healthy?

Macleod Pharmaceuticals has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.

Should I do business with Macleod Pharmaceuticals?

Its overall Trust Score is 90/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Macleod Pharmaceuticals?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Macleod Pharmaceuticals have loans or charges against its assets?

No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Macleod Pharmaceuticals up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Macleod Pharmaceuticals?

Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.